BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 22880004)

  • 41. Characterisation of the p53 pathway in cell lines established from TH-MYCN transgenic mouse tumours.
    Chen L; Esfandiari A; Reaves W; Vu A; Hogarty MD; Lunec J; Tweddle DA
    Int J Oncol; 2018 Mar; 52(3):967-977. PubMed ID: 29393340
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Expression of a mutant p53 results in an age-related demographic shift in spontaneous lung tumor formation in transgenic mice.
    Duan W; Gao L; Wu X; Hade EM; Gao JX; Ding H; Barsky SH; Otterson GA; Villalona-Calero MA
    PLoS One; 2009; 4(5):e5563. PubMed ID: 19440353
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cancer type-dependent correlations between TP53 mutations and antitumor immunity.
    Li L; Li M; Wang X
    DNA Repair (Amst); 2020 Apr; 88():102785. PubMed ID: 32007736
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Role of KEAP1/NRF2 and TP53 Mutations in Lung Squamous Cell Carcinoma Development and Radiation Resistance.
    Jeong Y; Hoang NT; Lovejoy A; Stehr H; Newman AM; Gentles AJ; Kong W; Truong D; Martin S; Chaudhuri A; Heiser D; Zhou L; Say C; Carter JN; Hiniker SM; Loo BW; West RB; Beachy P; Alizadeh AA; Diehn M
    Cancer Discov; 2017 Jan; 7(1):86-101. PubMed ID: 27663899
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Expression signatures of metastatic capacity in a genetic mouse model of lung adenocarcinoma.
    Gibbons DL; Lin W; Creighton CJ; Zheng S; Berel D; Yang Y; Raso MG; Liu DD; Wistuba II; Lozano G; Kurie JM
    PLoS One; 2009; 4(4):e5401. PubMed ID: 19404390
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Somatic loss of BRCA1 and p53 in mice induces mammary tumors with features of human BRCA1-mutated basal-like breast cancer.
    Liu X; Holstege H; van der Gulden H; Treur-Mulder M; Zevenhoven J; Velds A; Kerkhoven RM; van Vliet MH; Wessels LF; Peterse JL; Berns A; Jonkers J
    Proc Natl Acad Sci U S A; 2007 Jul; 104(29):12111-6. PubMed ID: 17626182
    [TBL] [Abstract][Full Text] [Related]  

  • 47. p53 loss does not permit escape from Braf
    Garnett S; Dutchak KL; McDonough RV; Dankort D
    Oncogene; 2017 Nov; 36(45):6325-6335. PubMed ID: 28745322
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Mutant p53(R270H) gain of function phenotype in a mouse model for oncogene-induced mammary carcinogenesis.
    Heinlein C; Krepulat F; Löhler J; Speidel D; Deppert W; Tolstonog GV
    Int J Cancer; 2008 Apr; 122(8):1701-9. PubMed ID: 18092324
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Clinical significance of mutant p53 protein expression in lung adenocarcinoma].
    Bian C; Li Z; Xu Y; Wang J; Xu L; Shen H
    Zhongguo Fei Ai Za Zhi; 2015 Jan; 18(1):23-8. PubMed ID: 25603869
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Analysis of genomic and transcriptomic variations as prognostic signature for lung adenocarcinoma.
    Zengin T; Önal-Süzek T
    BMC Bioinformatics; 2020 Sep; 21(Suppl 14):368. PubMed ID: 32998690
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups.
    Curtis C; Shah SP; Chin SF; Turashvili G; Rueda OM; Dunning MJ; Speed D; Lynch AG; Samarajiwa S; Yuan Y; Gräf S; Ha G; Haffari G; Bashashati A; Russell R; McKinney S; ; Langerød A; Green A; Provenzano E; Wishart G; Pinder S; Watson P; Markowetz F; Murphy L; Ellis I; Purushotham A; Børresen-Dale AL; Brenton JD; Tavaré S; Caldas C; Aparicio S
    Nature; 2012 Apr; 486(7403):346-52. PubMed ID: 22522925
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Telomere dysfunction promotes genome instability and metastatic potential in a K-ras p53 mouse model of lung cancer.
    Perera SA; Maser RS; Xia H; McNamara K; Protopopov A; Chen L; Hezel AF; Kim CF; Bronson RT; Castrillon DH; Chin L; Bardeesy N; Depinho RA; Wong KK
    Carcinogenesis; 2008 Apr; 29(4):747-53. PubMed ID: 18283039
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Intestinal cancer progression by mutant p53 through the acquisition of invasiveness associated with complex glandular formation.
    Nakayama M; Sakai E; Echizen K; Yamada Y; Oshima H; Han TS; Ohki R; Fujii S; Ochiai A; Robine S; Voon DC; Tanaka T; Taketo MM; Oshima M
    Oncogene; 2017 Oct; 36(42):5885-5896. PubMed ID: 28628120
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Survival in males with glioma and gastric adenocarcinoma correlates with mutant p53 residual transcriptional activity.
    Fischer NW; Prodeus A; Gariépy J
    JCI Insight; 2018 Aug; 3(15):. PubMed ID: 30089713
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A mouse model for tumor progression of lung cancer in ras and p53 transgenic mice.
    Wang Y; Zhang Z; Lubet RA; You M
    Oncogene; 2006 Feb; 25(8):1277-80. PubMed ID: 16247444
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Mice with alterations in both p53 and Ink4a/Arf display a striking increase in lung tumor multiplicity and progression: differential chemopreventive effect of budesonide in wild-type and mutant A/J mice.
    Wang Y; Zhang Z; Kastens E; Lubet RA; You M
    Cancer Res; 2003 Aug; 63(15):4389-95. PubMed ID: 12907609
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Enhanced prediction of breast cancer prognosis by evaluating expression of p53 and prostate-specific antigen in combination.
    Yu H; Levesque MA; Clark GM; Diamandis EP
    Br J Cancer; 1999 Oct; 81(3):490-5. PubMed ID: 10507775
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Mutations of the p53 gene as a predictor of poor prognosis in patients with non-small-cell lung cancer.
    Mitsudomi T; Oyama T; Kusano T; Osaki T; Nakanishi R; Shirakusa T
    J Natl Cancer Inst; 1993 Dec; 85(24):2018-23. PubMed ID: 8246288
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Immune landscape and a promising immune prognostic model associated with TP53 in early-stage lung adenocarcinoma.
    Wu C; Rao X; Lin W
    Cancer Med; 2021 Feb; 10(3):806-823. PubMed ID: 33314730
    [TBL] [Abstract][Full Text] [Related]  

  • 60. SETDB1 Inhibits p53-Mediated Apoptosis and Is Required for Formation of Pancreatic Ductal Adenocarcinomas in Mice.
    Ogawa S; Fukuda A; Matsumoto Y; Hanyu Y; Sono M; Fukunaga Y; Masuda T; Araki O; Nagao M; Yoshikawa T; Goto N; Hiramatsu Y; Tsuda M; Maruno T; Nakanishi Y; Hussein MS; Tsuruyama T; Takaori K; Uemoto S; Seno H
    Gastroenterology; 2020 Aug; 159(2):682-696.e13. PubMed ID: 32360551
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.